

## News Release

Company name TMS Co., Ltd.  
Name of representative: Takuro Wakabayashi, Co., Ltd.  
Chief Executive Officer  
(Securities code: 4891; Growth Market)

**TMS was selected as a finalist of the Citeline Pharma Intelligence Awards Japan 2023**

We are pleased to announce that TMS Co., Ltd., (the “Company”) has been selected as a finalist of the "Biotech Company of the Year" and "Financing Deal of the Year" categories in the "Citeline Pharma Intelligence Awards Japan 2023".

Please check the following site for more details.

**About TMS**

TMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases to address medical unmet needs. The Company’s pipeline consists of a family of small compounds called SMTPs (Stachybotrys microspora triprenyl phenols) derived from a fungus. The lead pipeline, TMS-007, is indicated for the treatment of acute ischemic stroke. It demonstrated efficacy and safety in the completed Phase 2 study and was acquired by Biogen in 2021. Another SMTP compound, TMS-008, is under development for acute kidney injury and other potential indications. In addition, the Company is exploring new pipelines by focusing on early-stage seeds from academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit [www.tms-japan.co.jp/en](http://www.tms-japan.co.jp/en).

Investor and Media Contact: [ir@tms-japan.co.jp](mailto:ir@tms-japan.co.jp)

End